HPS Pharmacies wish to advise that Hospira, in consultation with the Therapeutic Goods Administration (TGA) have given notice of an urgent drug recall of:
DBL™ Mitoxantrone 20mg/10mL Injection
Aust R.: 2469
Batch Number: A02463AA
Expiry Date: July 2015
This recall has been issued due to the identification of an impurity during long-term stability testing. The impurity is similar to the active pharmaceutical ingredient, mitozantrone, and is not expected to present a risk to patient safety. This batch is, however, out of specification and potentially offers inferior potency.
No adverse events associated with this batch have been reported.
This recall will result in a shortage of DBL™ Mitoxantrone 20mg/10mL injection until the next batch is released at the end of January 2015.
In the interim, a number of alternate brands may be used, two of which are included in the Pharmaceutical Benefits Scheme.
No other batches of DBL™ Mitoxantrone 20mg/10mL injection are affected by this recall.
Please inspect your stocks and quarantine all units for return to your supplier. Any items supplied by HPS Pharmacies should be returned to the pharmacy for processing.
Retain this notice in a prominent position, including in other related business units until normal supply resumes. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Hospira directly on 1300 046 774 or email@example.com.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.